Wall Street brokerages forecast that Omnicell, Inc. (NASDAQ:OMCL) will report sales of $177.37 million for the current quarter, according to Zacks. Two analysts have provided estimates for Omnicell’s earnings, with the highest sales estimate coming in at $177.41 million and the lowest estimate coming in at $177.32 million. Omnicell posted sales of $150.55 million in the same quarter last year, which suggests a positive year-over-year growth rate of 17.8%. The company is expected to issue its next earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Omnicell will report full-year sales of $177.37 million for the current fiscal year, with estimates ranging from $788.21 million to $790.51 million. For the next fiscal year, analysts anticipate that the company will report sales of $879.58 million per share, with estimates ranging from $867.46 million to $898.15 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Omnicell.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million during the quarter, compared to analysts’ expectations of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company posted $0.37 earnings per share.
Several research firms recently commented on OMCL. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price target on shares of Omnicell in a report on Wednesday, December 13th. Oppenheimer restated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Monday, January 29th. BidaskClub cut shares of Omnicell from a “sell” rating to a “strong sell” rating in a report on Friday, January 19th. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, Craig Hallum lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $56.14.
In related news, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Randall A. Lipps sold 8,186 shares of Omnicell stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total transaction of $361,903.06. Following the completion of the transaction, the chairman now directly owns 224,206 shares in the company, valued at approximately $9,912,147.26. The disclosure for this sale can be found here. 3.77% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. Elkfork Partners LLC bought a new position in shares of Omnicell in the fourth quarter valued at approximately $225,000. Xact Kapitalforvaltning AB bought a new position in shares of Omnicell in the fourth quarter valued at approximately $244,000. Martin & Co. Inc. TN raised its position in shares of Omnicell by 7.6% in the fourth quarter. Martin & Co. Inc. TN now owns 65,165 shares of the company’s stock valued at $3,161,000 after purchasing an additional 4,600 shares during the period. Pier Capital LLC raised its position in shares of Omnicell by 9.6% in the fourth quarter. Pier Capital LLC now owns 117,875 shares of the company’s stock valued at $5,717,000 after purchasing an additional 10,363 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Omnicell in the fourth quarter valued at approximately $812,000.
Shares of Omnicell (OMCL) opened at $44.25 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38. The company has a market cap of $1,727.79, a P/E ratio of 86.47, a P/E/G ratio of 3.67 and a beta of 0.75. Omnicell has a fifty-two week low of $38.00 and a fifty-two week high of $55.40.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $177.37 Million” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/analysts-expect-omnicell-inc-omcl-will-announce-quarterly-sales-of-177-37-million.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Get a free copy of the Zacks research report on Omnicell (OMCL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.